Logo image of SLRN

ACELYRIN INC (SLRN) Stock Fundamental Analysis

NASDAQ:SLRN - Nasdaq - US00445A1007 - Common Stock - Currency: USD

2.6  +0.43 (+19.82%)

After market: 2.6 0 (0%)

Fundamental Rating

3

Overall SLRN gets a fundamental rating of 3 out of 10. We evaluated SLRN against 571 industry peers in the Biotechnology industry. While SLRN has a great health rating, there are worries on its profitability. SLRN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLRN had negative earnings in the past year.
In the past year SLRN has reported a negative cash flow from operations.
SLRN Yearly Net Income VS EBIT VS OCF VS FCFSLRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

With a Return On Assets value of -42.76%, SLRN perfoms like the industry average, outperforming 52.75% of the companies in the same industry.
The Return On Equity of SLRN (-50.05%) is better than 65.19% of its industry peers.
Industry RankSector Rank
ROA -42.76%
ROE -50.05%
ROIC N/A
ROA(3y)-37.51%
ROA(5y)N/A
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLRN Yearly ROA, ROE, ROICSLRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRN Yearly Profit, Operating, Gross MarginsSLRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

SLRN has more shares outstanding than it did 1 year ago.
There is no outstanding debt for SLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLRN Yearly Shares OutstandingSLRN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M
SLRN Yearly Total Debt VS Total AssetsSLRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -0.77, we must say that SLRN is in the distress zone and has some risk of bankruptcy.
SLRN has a better Altman-Z score (-0.77) than 60.21% of its industry peers.
There is no outstanding debt for SLRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.77
ROIC/WACCN/A
WACCN/A
SLRN Yearly LT Debt VS Equity VS FCFSLRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

SLRN has a Current Ratio of 7.15. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
SLRN has a Current ratio of 7.15. This is in the better half of the industry: SLRN outperforms 68.03% of its industry peers.
SLRN has a Quick Ratio of 7.15. This indicates that SLRN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.15, SLRN is doing good in the industry, outperforming 68.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.15
Quick Ratio 7.15
SLRN Yearly Current Assets VS Current LiabilitesSLRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

SLRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -455.27%.
EPS 1Y (TTM)-455.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLRN will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.46% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.08%
EPS Next 2Y22.06%
EPS Next 3Y14.6%
EPS Next 5Y11.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRN Yearly Revenue VS EstimatesSLRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SLRN Yearly EPS VS EstimatesSLRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRN Price Earnings VS Forward Price EarningsSLRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRN Per share dataSLRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

SLRN's earnings are expected to grow with 14.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.06%
EPS Next 3Y14.6%

More info and screens

0

5. Dividend

5.1 Amount

SLRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACELYRIN INC

NASDAQ:SLRN (2/21/2025, 8:00:02 PM)

After market: 2.6 0 (0%)

2.6

+0.43 (+19.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-28 2025-03-28/amc
Inst Owners89.36%
Inst Owner Change0.78%
Ins Owners1.13%
Ins Owner Change6.39%
Market Cap261.82M
Analysts78.46
Price Target10.54 (305.38%)
Short Float %7.22%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.99%
Min EPS beat(2)-11.91%
Max EPS beat(2)39.89%
EPS beat(4)3
Avg EPS beat(4)23.87%
Min EPS beat(4)-11.91%
Max EPS beat(4)63.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.33%
PT rev (3m)-15.38%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)10.17%
EPS NY rev (1m)1.25%
EPS NY rev (3m)14.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-2.68
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-2.55
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS5.25
TBVpS5.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.76%
ROE -50.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.51%
ROA(5y)N/A
ROE(3y)-42.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 388.92%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.15
Quick Ratio 7.15
Altman-Z -0.77
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-455.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.68%
EPS Next Y41.08%
EPS Next 2Y22.06%
EPS Next 3Y14.6%
EPS Next 5Y11.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-510.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.35%
EBIT Next 3Y14.86%
EBIT Next 5YN/A
FCF growth 1Y-179.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-175.85%
OCF growth 3YN/A
OCF growth 5YN/A